1941. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
作者: Frank Jühling.;Nourdine Hamdane.;Emilie Crouchet.;Shen Li.;Houssein El Saghire.;Atish Mukherji.;Naoto Fujiwara.;Marine A Oudot.;Christine Thumann.;Antonio Saviano.;Armando Andres Roca Suarez.;Kaku Goto.;Ricard Masia.;Mozhdeh Sojoodi.;Gunisha Arora.;Hiroshi Aikata.;Atsushi Ono.;Parissa Tabrizian.;Myron Schwartz.;Stephen J Polyak.;Irwin Davidson.;Christian Schmidl.;Christoph Bock.;Catherine Schuster.;Kazuaki Chayama.;Patrick Pessaux.;Kenneth K Tanabe.;Yujin Hoshida.;Mirjam B Zeisel.;François Ht Duong.;Bryan C Fuchs.;Thomas F Baumert.
来源: Gut. 2021年70卷1期157-169页
Hepatocellular carcinoma (HCC) is the fastest-growing cause of cancer-related mortality with chronic viral hepatitis and non-alcoholic steatohepatitis (NASH) as major aetiologies. Treatment options for HCC are unsatisfactory and chemopreventive approaches are absent. Chronic hepatitis C (CHC) results in epigenetic alterations driving HCC risk and persisting following cure. Here, we aimed to investigate epigenetic modifications as targets for liver cancer chemoprevention.
|